Spring direct naar de hoofdnavigatie of de inhoud
‘To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.’
Frits Michiels

Frits Michiels

  • Life Sciences
  • European and Dutch Patent Attorney
  • Valuation specialist
  • Partner

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups, such as Agendia and Merus. He has worked for V.O. since 2006.

Continue reading

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Merus (2006)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

Also see these experts

Jetze Beeksma

Jetze Beeksma

  • European and Dutch Patent Attorney, European Patent Litigator
  • Partner
Bettina Hermann

Bettina Hermann

  • European and German Patent and Trademark Attorney, European Patent Litigator
  • Partner
More experts

News

IP rights watch: avoid surprises

As an entrepreneur, you are constantly innovating and building your brand. But do you also keep track of what your competitors are doing in the IP field? Professional monitoring of patents and trademarks keeps you informed and prevents costly surprises.Continue reading

Your patent portfolio in safe hands: timely payment of annual fees

Your patent is a valuable intellectual asset that protects the core of your innovation and competitive advantage. Maintaining that protection is essential and requires meticulous management. An important aspect, for example, is the periodic timely payment of annual fees. Missing a payment deadline can lead to complications, additional costs and, in the worst case, even […]Continue reading

Awards for innovation

The importance of innovation was emphasised again this year by the awarding of the 2025 Nobel Prize in Chemistry and the ‘Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel’ — often referred to as the Nobel Prize in Economics.Continue reading